Document Detail

Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs.
MedLine Citation:
PMID:  18221087     Owner:  NLM     Status:  MEDLINE    
Maintenance of endothelial cells (ECs), the building blocks of the vascular tree, is a presumed function of fibroblast growth factors (FGFs). In particular, the two prototypic members of FGF family, namely FGF1 and FGF2, due to their potent mitogenic and pro-migratory activities, have the ability to induce metabolic and phenotypic changes in ECs that are required to stimulate angiogenesis. In addition to FGF1 and FGF2, 23 other members of the FGF family have since been identified and characterized and they are reviewed in relation to their disease pathology. Particular emphasis is given to the biology of the FGFs and FGFRs on how they mediate the onset of angiogenesis. The focus of the present review is to survey what is known about the role of the currently identified FGFs and their four high affinity tyrosine kinase receptors in diseases and the angiogenesis-targeted drugs currently in clinical trials. Some new and promising patented drugs that target the angiogenic pathway are discussed. Examination of the currently patented drugs may identify more potent and specific regulators of FGF/FGFR signaling system for treatment of tumor angiogenesis in clinical settings. Additionally, novel drug development strategies are highlighted and reviewed.
Gregory J Chen; Reza Forough
Related Documents :
16240117 - Thiosugars: new perspectives regarding availability and potential biochemical and medic...
14633727 - Rac1 and rac3 are targets for geranylgeranyltransferase i inhibitor-mediated inhibition...
20050847 - On setting the first dose in man: quantitating biotherapeutic drug-target binding throu...
3139807 - X-ray affinity and photoaffinity inhibitor of aldose reductase.
23196317 - Gingival overgrowth and drug association: a review.
10837707 - Cyclodextrins in targeting. application to nanoparticles.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Recent patents on cardiovascular drug discovery     Volume:  1     ISSN:  1574-8901     ISO Abbreviation:  Recent Pat Cardiovasc Drug Discov     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2008-01-28     Completed Date:  2008-02-15     Revised Date:  2011-11-10    
Medline Journal Info:
Nlm Unique ID:  101263805     Medline TA:  Recent Pat Cardiovasc Drug Discov     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  211-24     Citation Subset:  IM    
Department of Translational Medicine and Systems Biology, The Cardiovascular Research Institute, College of Medicine, The Texas A&M University Systems Health Science Center, College Station, TX 77843, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / etiology
Clinical Trials as Topic
Drug Design
Fibroblast Growth Factors / antagonists & inhibitors,  physiology*
Inflammation / etiology
Neoplasms / blood supply
Neovascularization, Pathologic / etiology
Receptors, Fibroblast Growth Factor / antagonists & inhibitors,  physiology*
Signal Transduction
Reg. No./Substance:
0/Receptors, Fibroblast Growth Factor; 62031-54-3/Fibroblast Growth Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of PPAR in cardiovascular diseases.
Next Document:  The renin inhibitor aliskiren as novel treatment for cardiovascular disease.